412 related articles for article (PubMed ID: 2259918)
21. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
23. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
[TBL] [Abstract][Full Text] [Related]
24. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
25. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Ho AD; del Valle F; Rückle H; Schwammborn J; Schlimok G; Hiddemann W; Meusers P; Thiel E; Dörken B; Hunstein W
Cancer; 1989 Oct; 64(7):1388-92. PubMed ID: 2776103
[TBL] [Abstract][Full Text] [Related]
26. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
28. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
[TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
[TBL] [Abstract][Full Text] [Related]
30. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.
Bergmann L; Karakas T; Knuth A; Lautenschläger G; Mitrou PS; Hoelzer D
Eur J Cancer; 1995 Dec; 31A(13-14):2164-8. PubMed ID: 8652236
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Bernell P; Kimby E; Hast R
Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
34. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
[TBL] [Abstract][Full Text] [Related]
36. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Wang WS; Tzeng CH; Chiou TJ; Liu JH; Fan S; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Feb; 57(2):100-5. PubMed ID: 8634923
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Hanazono Y; Miyazono K; Piao YF; Taketazu F; Chiba S; Miyagawa K; Hirai H; Sakamoto S; Miura Y; Yazaki Y
Int J Hematol; 1992 Jun; 55(3):243-8. PubMed ID: 1379844
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
39. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
40. High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.
Nissen NI; Hansen SW
Semin Oncol; 1990 Dec; 17(6 Suppl 10):10-2; discussion 12-3. PubMed ID: 2259917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]